Inhibit platelet aggregation by irreversibly inhibiting cyclo-oxygenase, reducing the synthesis of thromboxane A2 (an inducer of platelet aggregation) for the life of the platelet.
Aspirin is indicated for:
Combinations of oral anticoagulants and platelet inhibitors increase bleeding risk and should be avoided in AF patients without another indication for platelet inhibition.
Bronchospasm, angioedema, urticaria and rhinitis have been precipitated by aspirin; there is also cross-reactivity with other NSAIDs.
Aspirin is not recommended for the prevention of thromboembolic events or stroke in people with AF.
Oral anticoagulation with warfarin or a NOAC reduces thromboembolic complications and cardiovascular events more effectively than aspirin alone or aspirin combined with a P2Y12 inhibitor. In addition, the bleeding risk with oral anticoagulation is similar to aspirin alone.